VaxCAR-001 / Vaxcell-Bio Therap, Y-Biologics - LARVOL DELTA

VaxCell-Bio partners with ProBio to accelerate CAR-related therapies development (Korea Biomedical Review) - "VaxCell-Bio...said it signed a memorandum of understanding (MOU) with ProBio, a global contract development and manufacturing organization (CDMO), to accelerate the development of its chimeric antigen receptor (CAR)-related therapies...Under this agreement, the two companies will collaborate on the development, manufacturing, and clinical processes of CAR therapies in compliance with good manufacturing practices (GMP), with a focus on antibody drug development, gene and cell therapy-based drug discovery, and the creation of advanced pharmaceutical manufacturing processes....VaxCell-Bio is optimistic that its partnership with ProBio, a company with extensive experience in cell therapy development and commercialization, will provide a solid foundation for its ongoing projects, including dual-target CAR-T, CAR-MILs, and CAR-NK platform therapies."

Licensing / partnership • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Hepatocellular Cancer • Multiple Myeloma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Vaxel Bio, Anti-PD-L1 CAR-T Treatment Patent Registration [Google translation] (HIT News) - "Vaxcell Bio...announced on the 14th that it has completed patent registration for 'VaxCAR-001', a chimeric antigen receptor T cell (CAR-T) treatment targeting PD-L1, an immune checkpoint protein....'We will further accelerate the development of a dual-target CAR-T treatment targeting PD-L1 and EphA2 for solid cancers. Following domestic patents, we will secure international patents to seek entry into the global market and technology transfer.'"

Patent • Pipeline update • Oncology • Solid Tumor

Vaxcell Bio forms a scientific advisory group and launches an integrated R&D center [Google translation] (HIT News) - "Vaxcell Bio...launched a new scientific advisory group and integrated and expanded its research and development (R&D) organization...Vaxcell Bio signed a one-year advisory contract with new scientific advisory committee members, including Dr. Byeong-wook Ryu, who has led the research and development of CAR-T treatments in the United States, and Professor Seung-hwan Lee, a professor at the University of Ottawa in Canada, who is considered an authority on immune cell therapy research and development. It was announced on the 14th that it was done....'With the joining of the two scientists, the research and development of CAR-T, CAR-NK, and CAR-MILs, the Vax-CAR platform built by Vaxcell Bio, will accelerate and will have the effect of being recognized externally.'"

Licensing / partnership • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor

Vaxcell Bio announces ‘anti-PD-L1 CAR-T’ data at AACR [Google translation] (Pinpoint News) - P=NA | N=NA | "Vaxcell Bio announced on the 21st that it will present the efficacy and toxicity test data of 'VaxCAR2301', an anti-PD-L1 CAR-T treatment for which it applied for an international patent last year, in a poster format at the American Association for Cancer Research (AACR) next month...On the other hand, the ratio of immune checkpoint proteins Tim-3, LAG-3, and TIGIT, which weaken immune cells' ability to kill cancer cells, was 8% each for VaxCAR2301. 39% and 13% for Avelumab CAR-T, respectively, 35%. 55%, 42%, and 19%, 51%, and 34% of atezolizumab CAR-T, respectively....'We plan to go one step further and develop PD-L1 targeting solid cancers. 'We will further accelerate the development of L1 and EphA2 dual-target CAR-T treatment,'..."

Clinical data • Solid Tumor

Y-Biologics transfers antibody sequence tech to VaxCell Bio (Korea Biomedical Review) - "Y-Biologics said Wednesday that it has signed a licensing-out deal with VaxCell Bio, a company specializing in anticancer immune cell therapies, for its anti-PD-L1 antibody 'YBL-007' sequence. Under the agreement, VaxCell Bio has the exclusive right to use the YBL-007 sequence in the research, development, and commercialization of CAR-T (chimeric antigen receptor T-cell) or CAR-NK (chimeric antigen receptor natural killer cell) therapeutics. YBL-007 is an antibody that targets the immune checkpoint protein PD-L1. The antibody binds to PD-L1 on the surface of cancer cells."

Licensing / partnership • Oncology

The efficacy and safety of PD-L1-specific CAR-T in advanced gastric cancer (AACR 2023) - "Despite high Tim3 and LAG3 expression in the final manufacturing process, Vax-CAR-T cells significantly suppressed tumor growth in both bigger (>95mm3) and smaller (≤50mm3) AGC xenograft NSG mouse models. More importantly, Vax-CAR-T-treated mice have well tolerated the CAR-T therapy with no significant adverse events during the CRS monitoring period, 2 weeks after Vax-CAR-T injection and have gradually recovered weight gains 5 days after CAR-T cell injection.[Conclusion] We believe that a new autologous CAR-T targeting PD-L1 could be a promising new tool for removing heterogeneous solid tumors in TME, which would be a significant step forward in improving current conventional and immunotherapeutic strategies."

Clinical • IO biomarker • Metastases • Gastric Cancer • Gastrointestinal Cancer • Microsatellite Instability • Oncology • Solid Tumor • HAVCR2 • IL2RA • LAG3 • MSI • PD-L1